The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2020 | SF3B1-mutant MDS: a new disease subtype
David Sallman, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the recognition of a distinct subtype of myelodysplastic syndrome (MDS) based on the presence of a genetic mutation known as SF3B1. Dr Sallman reveals that patients with MDS who carry this genetic variant have a relatively good prognosis. Additionally, a recent clinical trial (MEDALIST; NCT02631070) showed that a high proportion of patients who carried the SF3B1 mutation responded to treatment with luspatercept. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
